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Abstract: Rationale/Objective: The Behavioral Risk Factor Surveillance System (BRFSS) health survey
has been used to describe the epidemiology of chronic obstructive pulmonary disease (COPD) in the
US. Through addressing respiratory symptoms and tobacco use, it could also be used to characterize
COPD risk. Methods: Four US states added questions to the 2015 BRFSS regarding productive
cough, shortness of breath, dyspnea on exertion, and tobacco duration. We determined COPD
risk categories: provider-diagnosed COPD as self-report, high-risk for COPD as ≥10 years tobacco
smoking and at least one significant respiratory symptom, and low risk was neither diagnosed COPD
nor high risk. Disease burden was defined by respiratory symptoms and health impairments. Data
were analyzed using multiple logistic regression models with age as a covariate. Results: Among
35,722 adults ≥18 years, the overall prevalence of COPD and high-risk for COPD were 6.6% and
5.1%. Differences among COPD risk groups were evident based on gender, race, age, geography,
tobacco use, health impairments, and respiratory symptoms. Risk for disease was seen early where
3.75% of 25–34 years-old met high-risk criteria. Longer tobacco duration was associated with an
increased prevalence of COPD, particularly >20 years. Seventy-nine percent of persons ≥45 years-old
with frequent shortness of breath (SOB) reported having or being at risk of COPD, reflecting disease
burden. Conclusion: These data, representing nearly 18% of US adults, indicates those at high risk
for COPD share many, but not all of the characteristics of persons diagnosed with the disease and
demonstrates the value of the BRFSS as a tool to define lung health at a population level.
Healthcare 2019, 7, 12; doi:10.3390/healthcare7010012 www.mdpi.com/journal/healthcare
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1. Introduction
Characterizing COPD at the population level through cross-sectional surveys is important to the
overall strategy to target the disease. Both the National Heart Lung and Blood Institute’s (NHLBI)
National COPD Action Plan [1] and the Center for Disease Control and Prevention’s (CDC) Public
Health Strategic Framework for COPD Prevention [2] recommend the expansion of epidemiologic
instruments in the USA to better characterize persons with and at risk for disease. One goal of the
National COPD Action Plan is to “enhance and optimize capacity” to collect epidemiologic data from
multiple sources, at various geographic levels, and to act upon these data.
The CDC has several surveillance tools that could be used to characterize the burden of COPD
in the population, in some instances in specific geographic regions as recommended by the NHLBI.
The nationally-based, state-administered BRFSS telephone health survey, conducted annually in
>400,000 adults, has been used to estimate COPD prevalence since 2007 [3]. Whereas the core BRFSS
includes questions regarding tobacco use as smoking status, it does not define tobacco intensity or
duration, key determinants of tobacco-related health risks [4]. In 2012, we used the BRFSS in one
state to better characterize persons with or at risk for COPD through the inclusion of tobacco smoking
duration and respiratory symptom questions [5]. To explore this approach in a larger population, we
used these same survey questions in 2015 to characterize adults at high-risk of COPD in four states,
that collectively represent 17.7% of the US adult population [6].
2. Methods
2.1. Study Population and Survey
State health departments collaborate with the Centers for Disease Control and Prevention (CDC) to
conduct the BRFSS. It is a random, digit-dialed cellphone and landline survey of non-institutionalized
adults ≥18 years, composed of a core section of >90 questions about socio-demographics, health risk
behaviors and characteristics, chronic diseases and preventive health practices. Individual states can
add supplementary questions. We added a module of four questions of the type and frequency of
respiratory symptoms and tobacco smoking duration in four state’s BRFSS in 2015. Florida (FL) and
Texas (TX) were selected due to a high number of reported COPD hospitalizations, Kentucky (KY)
because of high COPD prevalence, and South Carolina (SC) to assess survey replicability compared to
2012 data. Combined, an estimated 18.7% of COPD patients reside in these states [7].
The BRFSS is approved as exempt research by the CDC. Survey response rates (proportion of all
eligible and likely-eligible persons) were calculated using standards by the American Association of
Public Opinion Research Response Rate Formula #4 (https://www.aapor.org/AAPOR_Main/media/
publications/Standard-Definitions2015_8theditionwithchanges_April2015_logo.pdf). The response
rates for each state were as follows—landline, cellphone, and combined: FL 37.0%, 37.1%, and
37.0%; KY 62.1%, 51.6%, and 59.0%; SC 52.1%, 51.5%, and 50.4%; TX 32.9%, 41.0%, and 34.4%.
The number of respondents were—FL (9739), KY (8806), SC (11,607), and TX (14,697). Detailed
information is available through the 2015 BRFSS Summary Data Quality Report at CDC BRFSS
(http://www.cdc.gov/surveillancepractice/reports/brfss/brfss.html).
Module questions were derived from COPD screening questionnaires [8–11] (Table 1) and are the
same as those added to the 2012 SC BRFSS [5]. To help differentiate between low and high-risk for
COPD, we did not include intermediate respiratory symptoms in the analysis such as productive cough
a few days each month. When shortness of breath (SOB) was reported as slightly or strongly associated
with physical activities, it was considered to represent dyspnea on exertion (DOE). Those with a
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positive smoking history were asked about life-time duration of tobacco smoking (tobacco-years).
Those with a positive smoking history were defined as those respondents answering affirmatively to
“Have you smoked at least 100 cigarettes in your entire life?” Those responding “no” were categorized
as never smokers (Table 1). Individuals responding “yes” were also asked, “Do you now smoke
cigarettes every day, some days, or not at all?” Persons who responded “not at all” were defined as
former smokers with the remainder defined as current smokers.
Table 1. Respiratory module and health impairment questions with possible responses using the 2015
Behavioral Risk Factor Surveillance System telephone health survey in four states (FL, KY, SC, TX).
Respiratory Symptom Module Definition of Affirmative Response
How many years have you smoked tobacco products?___ yrs
(Above question asked if respondent answered affirmatively to
the following—Have you smoked more than 100 cigarettes in
your lifetime?
≥10 years of tobacco smoking
(10 tobacco-years) considered risk factor
for developing COPD.
During the past 30 days, how often do you feel short of
breath?—would you say all of the time, most of the time, some
of the time, a little of the time, or none of the time?
Frequent SOB defined as all of the time or
most of the time.
During the past 30 days, how often do you cough up mucus or
phlegm? Would you say . . . ? Every day, Most days, A few
days, Only with colds, or Never.
Frequent productive cough defined as
every day or most days.
How much do you agree or disagree with the following
statement? In the past year, I am not as physically active as I
once was because of my shortness of breath. Agree strongly,
Agree slightly, Neither agree or disagree, Disagree slightly,
Disagree strongly.
Dyspnea on exertion defined as agreeing
strongly or slightly.
Health Impairment Definition of Affirmative Response
Would you say your general health is . . . excellent, very good,
good, fair, or poor? A reply of fair or poor.
Now thinking about your mental health, which includes stress,
depression, and problems with emotions, for how many days
during the past 30 days was your mental health not good?
Frequent mental distress was defined as a
response of ≥14 days to the question.
Now thinking about your physical health, which includes
physical illness and injury, for how many days during the past
30 days was your physical health not good?
Frequent physical distress was defined as
a response of ≥14 days to the question.
Do you have serious difficulty walking or climbing stairs? A reply of yes.
2.2. COPD Risk Groups
Among persons ≥18 years-old, three COPD risk groups were determined based upon self-report
of diagnosis, respiratory symptoms, and tobacco-years. Diagnosed COPD was a self-report of
provider-diagnosed disease; high-risk for COPD were respondents with no COPD diagnosis,
≥10 tobacco-years, and ≥1 significant respiratory symptom (frequent productive cough, frequent SOB,
or DOE); and low-risk as neither diagnosed COPD nor at high-risk.
2.3. Disease Burden
Questions and affirmative responses for health impairment are shown in Table 1. Other measures
of disease burden included comorbidity frequencies. The BRFSS includes questions regarding
comorbidities as depression, asthma, coronary heart disease, and arthritic among others based on
self-report of provider diagnosis. Body mass index (BMI) was determined from reported height and
weight without shoes and categorized using World Health Organization classifications [12].
2.4. Analysis
Respondents were excluded from analysis for missing data on COPD history, smoking status,
smoking duration, or one or more respiratory symptoms. All analyses were conducted using SAS 9.4 to
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account for the complex BRFSS sampling. Analysis was done collectively for all states and for selected
measures by individual state. First, we calculated the percentage and 95% confidence intervals (CI)
of socio-demographics, health behaviors, health impairment, and chronic diseases. For comparisons
of prevalence’s between subgroups, statistical significance was determined by t-tests. We tested for
linear trends across categories (e.g., tobacco duration and age) using the Wald F-statistic. Age-adjusted
prevalence and 95% CI of selected characteristics by COPD risk status, age, tobacco duration, was
calculated. Prevalence was compared by risk status using pairwise t-tests. A p-value <0.05 was
considered statistically significant for all tests.
3. Results
A total of 44,849 subjects ≥18 years-old were asked core BRFSS questions including COPD
prevalence. The module of four questions to determine COPD risk was asked of all states’ respondents
over the 12-month period except FL where this was asked over 6 months. After exclusion of subjects
with incomplete data there were 35,722 subjects’ data analyzed. More than half of the respondents were
≥45 years-old, female, Caucasian, and at least some college education. Hispanic and African-American
minorities were well represented (Table 2).
3.1. COPD Risk
Table 2 shows the socio-demographics, smoking status, and tobacco-years among the COPD
risk groups. Among adults over 18 years-old, the overall self-reported, provider-diagnosed COPD
prevalence was 6.6% and high-risk for COPD was 5.1%. Women reported higher age-adjusted
prevalence of COPD (p < 0.05), whereas men were more likely to be at high-risk for COPD (p < 0.05).
Caucasians and multi-racial persons had the highest rates of provider-diagnosed COPD and Hispanics
the lowest (p < 0.05); Caucasians also reported the highest prevalence of high-risk for COPD. Those
with <high school education had higher rates of COPD and at high-risk for COPD than those with
a college education (p < 0.05). Figure 1 shows the frequencies of COPD, at-high risk for COPD,
respiratory symptoms and current smoking status for each age group. The prevalence of high-risk
was 3.75% in the 25–34 years age group, further increased with age and then remained relatively
stable after 44 years-old. After DOE, frequent productive cough was the next most common symptom
(Figure 1). The increase in COPD prevalence was most evident between the 45–54 years-old and
54–65 years-old age groups. Combined, nearly 60% of persons at high-risk for COPD were in the 45–54
and 55–64 years-old age groups.
3.2. Tobacco Smoking
The frequencies of high-risk for COPD and self-report of provider-diagnosed COPD,
in relationship to tobacco status and tobacco-years are shown in Table 2. 72.6% (95% CI 71.4–73.7)
of persons in the low risk group were never smokers and 9.3% (95% CI 8.5–10.1) smoked <10 years.
Figure 1 shows current smoking rates among age groups for the four states combined and Figure 2
shows data for individual states. The risk of self-reported COPD was most apparent with >20 years
of smoking, with rates exceeding 30% in those with >30 years. Current smoking rates peaked in the
25–34 years-old age group, remained somewhat stable until the 55–64 years-old age group, declining
thereafter (Figures 1 and 2).
3.3. Comorbidities
Comorbid conditions among COPD groups are shown in Table 3. All comorbidities occurred
more often in high-risk for COPD and COPD groups compared to low-risk, except cancers. The most
common chronic illnesses in the high-risk and COPD groups were depression and arthritis, followed
by asthma. Some differences in frequency of comorbidities between high-risk and COPD groups were
found. Concurrent asthma was reported in nearly 10% of persons at high-risk of COPD and by more
than a third of COPD patients—two to four-fold greater than the low-risk group.
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Figure 1. Age group specific prevalence of respiratory symptoms, current smoking, and COPD risk in
adults ≥18 years-old using the 2015 Behavioral Risk Factor Surveillance System telephone survey in
four states (FL, KY, SC, TX).
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Behavioral Risk Factor Surveillance System h alth survey.
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Table 2. Age adjusted prevalence and 95% confidence intervals (CI) of selected characteristics adults aged ≥18 years by COPD risk status a–c using BRFSS, 2015
among Four States (FL, KY, SC, TX).
Characteristic
DN with COPD a
(n = 3915) (%, 95% CI)
HR for COPD b
(n = 2399) (%, 95% CI)
LR for COPD c
(n = 29,585) (%, 95% CI)
Contrast (P-Value)
DN vs. HR DN vs. LR HR vs. LR
Mean Age (Years, 95% CI) 59.0 (57.7–62.0) 55.2 (53.7–56.8) 46.4 (46.0–46.8) < 0.001 <0.001 <0.001
Overall 6.6 (6.1–7.1) 5.1 (4.6–5.6) 88.2 (87.6–89.0) <0.001 <0.001 <0.001
Socio-demographics
Sex
Men 6.2 (5.4–6.9) 6.3 (5.5–7.1) 87.6 (86.5–88.6) NS <0.001 <0.001
Women 7.0 (6.4–7.7) 4.1 (3.5–4.9) 88.8 (87.9–89.7) <0.001 <0.001 <0.001
Age (years) (Not
age-adjusted)
18–25 2.7 (1.1–4.3) 0.3 (0.0–0.6) 97.1 (95.4–98.7) <0.001 <0.001 <0.001
25–34 2.4 (1.5–3.4) 3.5 (1.8–5.2) 84.1 (92.2–96.0) <0.001 <0.001 <0.001
35–44 3.4 (2.7–4.7) 4.8 (3.6–6.0) 91.8 (90.3–93.3) NS <0.001 <0.001
45–54 6.5 (6.1–8.7) 6.6 (5.2–8.0) 86.9 (85.1–88.7) NS <0.001 <0.001
55–64 12.4 (10.9–13.8) 7.4 (6.3–8.6) 80.1 (78.3–82.0) <0.001 <0.001 <0.001
65–74 13.4 (11.9–14.9) 7.7 (6.4–9.0) 78.9 (77.0–80.8) <0.001 <0.001 <0.001
≥75 15.6 (13.7–17.5) 7.8 (6.5–9.0) 76.6 (74.5–78.8) <0.001 <0.001 <0.001
Race
White—Non-Hispanic 7.8 (7.1–8.5) 6.5 (5.6–7.3) 85.7 (84.6–86.8) <0.001 <0.001 <0.001
Black—Non-Hispanic 5.4 (4.0–6.8) 3.5 (2.6–4.4) 91.1 (89.5–92.7) NS <0.001 <0.001
Hispanic 4.2 (3.1–5.3) 3.3 (2.4–4.2) 92.5 (91.1–93.9) NS <0.001 <0.001
Other race only,
Non-Hispanic 8.6 (3.4–9.8) 5.6 (2.8–8.4) 87.8 (83.7–91.9) NS <0.001 <0.001
Multiracial,
Non-Hispanic 11.2 (6.5–15.9) 8.7 (2.0–15.4) 80.1 (72.3–88.0) NS <0.001 <0.001
Education
< High School 9.1 (7.8–10.5) 6.6 (5.6–9.7) 83.3 (80.9–85.7) NS <0.001 <0.001
High School
Graduate 7.8 (6.8–8.8) 6.4 (5.3–7.5) 85.7 (84.3–87.2) NS <0.001 <0.001
Some College 6.6 (5.6–7.5) 5.2 (4.3–6.1) 88.3 (87.0–89.5) <0.001 <0.001 <0.001
College Graduate 3.6 (2.9–4.2) 2.3 (1.8–2.7) 94.2 (93.4–94.9) <0.001 <0.001 <0.001
Risk factors
Smoking status
Current smoker 18.2 (15.9–20.4) 21.4 (18.5–24.2) 60.5 (57.2–63.7) NS <0.001 <0.001
Former smoker 8.2 (7.1–9.4) 8.5 (7.0–10.1) 83.2 (81.4–85.19) NS <0.001 <0.001
Never smoker 3.0 (2.6–3.5) ~ ~ 96.9 (95.5–97.4) <0.001 <0.001 <0.001
Tobacco smoking
duration (years)
(Not age-adjusted)
Never smoked 3.0 (2.6–3.5) ~ ~ 97.0 (96.5–97.4) <0.001 <0.001 <0.001
1–9 5.0 (3.7–6.4) ~ ~ 95.0 (93.6–96.3) <0.001 <0.001 <0.001
10–19 8.4 (6.4–10.4) 23.5 (19.9–27.1) 68.1 (63.3–71.8) <0.001 <0.001 <0.001
20–29 16.8 (14.1–18.4) 21.8 (18.9–24.6) 61.5 (58.0–64.9) <0.001 <0.001 <0.001
≥30 31.1 (28.3–33.9) 23.9 (21.2–26.6) 45.0 (41.9–64.9) <0.001 <0.001 <0.001
DN: Diagnosed; HR: High-Risk; LR: Low-Risk. a Diagnosed-Self-reported physician diagnosis of COPD; b High-risk-No COPD diagnosis, ≥10 years of cigarette/tobacco use, and at least
one respiratory symptom (frequent productive cough, frequent shortness of breath (SOB), or breathing problems limited physical activity in past year.); c Low-risk—Neither diagnosed
with nor high-risk for COPD.
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Table 3. Age adjusted prevalence and 95% confidence intervals (95% CI) of health characteristics and respiratory symptoms in adults aged ≥18 years by COPD risk
status a—BRFSS, 2015 among four states (FL, KY, SC, TX).
Characteristic
DN with COPD (n = 3915)
(%, 95% CI)
HR for COPD (n = 2399)
(%, 95% CI)
LR for COPD (n = 29,585)
(%, 95% CI)
Comparison of Groups (P-Value)
DN vs. HR DN vs. LR HR vs. LR
Chronic Conditions
Current asthma 34.6 (29.7–39.4) 8.7 (5.7–11.6) 4.6 (4.1–5.2) <0.001 <0.001 <0.001
Coronary heart disease 15.0 (12.2–17.7) 10.4 (7.9–12.9) 3.5 (3.1–3.9) NS <0.001 <0.001
Diabetes mellitus 22.4 (18.8–25.9) 17.1 (13.9–20.2) 13.0 (12.1–13.9) NS <0.001 <0.001
Arthritis 59.8 (54.1–65.6) 42.0 (37.0–47-0) 25.7 (24.6–26.8) <0.001 <0.001 <0.001
Cancer (excluding skin) 7.8 (4.9–10.8) 4.1 (2.7–5.3) 3.5 (3.0–3.9) NS <0.001 NS
Depression 48.2 (42.6–53.9) 33.1 (28.0–38.2) 13.2 (12.2–14.2) <0.001 <0.001 <0.001
Stroke 11.7 (9.0–14.4) 6.0 (4.3–7.6) 2.8 (2.4–3.1) <0.001 <0.001 <0.001
Kidney disease 10.3 (5.7–14.9) 4.5 (3.0–5.9) 2.7 (2.3–3.1) NS <0.001 NS
Health Impairment
Fair/poor health b 53.5 (48.1–60.0 38.1 (32.7–43.4) 17.1 (16.0–18.3) <0.01 <0.001 <0.001
Frequent mental distress c 55.4 (48.7–62.1) 46.7 (39.0–54.3) 30.8 (28.2–33.4) NS <0.001 <0.001
Frequent physical distress d 58.3 (51.4–65.2) 48.6 (41.2–55.9) 33.4 (30.8–36.0) NS <0.001 <0.001
Difficulty walking or climbing
stairs e 47.7 (42.7–52.7) 32.6 (27.9–37.4) 13.0 (12.2–13.8) <0.01 <0.01 <0.01
Respiratory Symptoms
Frequent shortness of breath f 29.6 (24.8–34.5) 13.0 (8.7–17.3) 14.3 (10.9–17.6) <0.01 <0.001 NS
Frequent productive cough g 37.6 (31.7–43.5) 39.5 (34.1–44.8) 3.7 (3.1–4.1) NS <0.001 <0.001
Dyspnea on exertion h 58.7 (52.8–64.5) 55.6 (50.5–60.8) 10.1 (9.1–11.1) NS <0.001 <0.001
DN: Diagnosed; HR: High-Risk; LR: Low-Risk. a Diagnosed-Self-reported physician diagnosis of COPD. High-risk-No COPD diagnosis, ≥10 years of cigarette/tobacco use, and at least
one respiratory symptom (frequent productive cough, frequent shortness of breath (SOB), or breathing problems limited physical activity in past year.) Low-risk-Neither diagnosed nor
high-risk. b Would you say that in general your health is excellent, very good, good, fair or poor? c Number of days mental health not good in last month ≥14 days? d Number of days
physical health not good in last month ≥14 days? e Do you have serious difficulty walking or climbing stairs; f Shortness of breath all of the time or most of the time in the last 30 days;
g Cough up phlegm or mucus every day or most days in the last 30 days; h Agree slightly or strongly that physical activity is affected by shortness of breath over the past year.
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3.4. Health Impairment
Among health impairment measures, fair or poor overall health status and difficulty walking or
climbing stairs were less frequent in the high-risk group than the COPD group (p < 0.05); physical and
mental distress were similar between these two groups. All health impairments were less frequent in
the low-risk group (p < 0.05). One-third of persons at high-risk for COPD and COPD reported frequent
productive cough, and was greater than the low-risk group (p < 0.05). Frequent SOB was the only
respiratory symptom significantly less common in those at high-risk versus COPD (p < 0.05).
3.5. State-Specific Data
The prevalence of high-risk for COPD, self-reported, provider-diagnosed COPD, and low-risk
for COPD from each state are shown in Table 4. Rates of high-risk for COPD and COPD ranged from
3.7–9.0% and 5.7–11.2%, respectively, and were highest in KY and lowest in TX, consistent with the
current-smoker rates for each state shown in Figure 2. Frequent SOB was reported in adults > 18
years-old (%, 95% CI) as follows: FL (3.4%, 2.4–4.4), KY (6.8%, 5.6–7.9), SC (3.8%, 3.3–4.3), and TX
(2.3%, 1.9–2.7). Among survey respondents ≥45 years-old in these states who reported frequent SOB,
nearly 80% of adults also reported either being diagnosed with COPD or were defined as high-risk for
COPD, also varying by state (Table 5).
Table 4. State-specific, age-adjusted prevalence of COPD risk-categories among adults ≥18 years-old
in each of the four states (FL, KY, SC, TX) using the 2015 Behavioral Risk Factor Surveillance system
telephone survey.
Characteristic
DN with COPD b
(n a = 3915)
(%, 95% CI)
HR for COPD b
(n a = 2399)
(%, 95% CI)
LR for COPD b
(n a = 29,585)
(%, 95% CI)
Comparison of Groups (P-Value)
DN vs. HR DN vs. LR HR vs. LR
Gender
Men 6.2 (5.4–6.9) 6.3 (5.5–7.1) 87.6 (86.5–88.6) NS <0.001 <0.001
Women 7.0 (6.4–7.7) 4.1 (3.5–4.9) 88.8 (87.9–89.7) <0.001 <0.001 <0.001
State
FL 6.5 (5.5–7.5) 5.6 (4.5–6.8) 87.2 (86.4–89.3) NS <0.001 <0.001
KY 11.2 (10.1–12.3) 9.0 (7.7–10.3) 79.8 (78.2–81.4) NS <0.001 <0.001
SC 7.1 (6.5–7.8) 6.1 (5.4–6.8) 86.7 (85.8–87.7) NS <0.001 <0.001
TX 5.7 (5.0–6.4) 3.7 (3.2–4.2) 90.5 (89.7–91.4) <0.001 <0.001 <0.001
DN: Diagnosed; HR: High-Risk; LR: Low-Risk. a Unweighted sample size; b Diagnosed-Self-reported physician
diagnosis of COPD. High-risk-No COPD diagnosis, ≥10 years of cigarette/tobacco use, and at least one respiratory
symptom (frequent productive cough, frequent shortness of breath (SOB), or breathing problems limited physical
activity in past year.) Low-risk-Neither diagnosed nor high-risk.
Table 5. State-specific, age-adjusted prevalence of frequent shortness of breath among COPD risk
categories among adults ≥45 years-old in each of the four states (FL, KY, SC, TX) using the 2015
Behavioral Risk Factor Surveillance system telephone survey.
Characteristic Diagnosed with COPD
b
(n a = 3915) (%, 95% CI)
High-risk for COPD b
(n a = 2399) (%, 95% CI)
Low-risk for COPD b
(n a = 29,585) (%, 95% CI)
Overall 62.4 (57.7–67.1) 16.7 (12.9–20.6) 20.8 (17.2–24.5)
State
Florida 69.0 (59.3–78.6) 17.7 (8.9–26.0) 13.3 (7.3–19.3)
Kentucky 66.0 (60.0–72.8) 13.7 (8.4–19.0) 19.9 (15.2–24.6)
South
Carolina 60.3 (53.7–66.9) 19.3 (14.2–24.4) 20.4 (15.0–25.9)
Texas 54.4 (45.5–62.3) 16.4 (11.3–21.4) 29.2 (21.9–36.5)
4. Discussion
We used a cross-sectional, population-based health survey in four states to better characterize
persons at significant risk of COPD consistent with expanding disease surveillance recommendations
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by the NHLBI and CDC. In a study of four states representing 17.7% of the US adult population,
using frequent respiratory symptoms and >10 years tobacco smoking history as risk factors, 5.1% of
adults were considered to be at high-risk for COPD and thus possibly undiagnosed or pre-disposed
to developing disease. A new finding from this study is that adults ≥45 years-old at high-risk of
COPD or reported having COPD accounted for 79.2% of adults who report frequent SOB, indicative
of the substantial disease burden at the population level. We also show that early COPD becomes
evident in young adults where 2.4% of 18–24 years-old reported provider-diagnosed COPD and 3.75%
of 25–34 years-old met the definition of being at high-risk. Further, this study demonstrates that
prolonged tobacco duration (tobacco-years) increases the likelihood of being at high-risk for COPD as
well as corroborates some less well-established findings as the association of tobacco duration and
increased risk of diagnosed COPD [13].
The BRFSS health survey is conducted annually in states throughout the USA and its territories,
thus incorporating respiratory symptoms and tobacco duration questions could be used to better
describe and monitor general lung health at different geographic levels. Strengths of the survey
include representation of the individual’s perspective of symptoms, behaviors and health impairments
not typically available in healthcare system databases. Respiratory symptom questions employed
for this study were derived from multiple questionnaires used to screen for COPD [8–11], and these
characterize the most common pulmonary symptoms associated with COPD—mucus production and
dyspnea—as well as the main risk factor for lung disease in the US—prolonged tobacco smoking [14].
Whereas the core BRFSS questions address a number of tobacco-related measures as status and
cessation attempts, it does not define tobacco smoking intensity nor duration, key factors affecting
tobacco-related morbidity and mortality [4]. Tobacco-years is a valid measure of risk, as duration is a
stronger predictor than intensity (pack-years) for risk of lung cancer [15], heart disease [16], as well as
COPD and emphysema [13]. Therefore, inclusion of tobacco duration is an important contribution to
the BRFSS.
Based on symptoms and tobacco smoking history, nearly as many adults >18 years-old were at
high-risk for COPD as there were persons reporting having COPD. In prior studies of persons with
undiagnosed COPD, airflow obstruction was most often mild, however, more severe disease was also
found [17,18]. Defining early or undiagnosed COPD can lead to higher smoking cessation rates [19],
but other benefits as increased survival are yet to be established, although some evidence shows
treatment in early, mild COPD slows decline in lung function [20,21]. The United States Preventive
Services Taskforce recommends the use of spirometry to screen for COPD in symptomatic persons [22].
As COPD is a leading cause of death in the USA, one could argue the best approach would be an
aggressive, comprehensive strategy to screen and diagnose disease. Studies as the RETHINC trial [23]
are evaluating benefits of pharmacological treatment of early disease.
There is increasing emphasis on targeting persons with early COPD, those at risk of developing
disease including young adults, as well as persons with COPD but are undiagnosed [1,2,24]. Using the
criteria of a minimum of 10 tobacco-years and at least one significant respiratory symptom, high-risk
for COPD was evident as early as 25 years-old (2.5%), the rate then increased, and plateaued at
45 years-old. This pattern could reflect persons eventually being diagnosed in their 40′s and 50′s, their
disease did not progress to COPD [25] or early mortality [26,27]. Smoking, environmental exposures,
and early life lung function are important determinants for lung function decline [25,28,29]. Smoking
rates were highest in the 25–34 years-old, likely a contributor to the respiratory symptoms as productive
cough in this age group and thus a self-report of a provider-diagnosis of COPD. Asthma early in
life appears to be an important risk factor for developing COPD, especially in smokers [25,28,29].
We found that asthma was more common in the high-risk group than the low-risk group, and the
greatest prevalence was in those with diagnosed COPD.
Martinez et al. proposed that early changes leading to COPD should be studied in persons
<50 years-old with ≥10 pack-years using objective measures as spirometry and radiography to define
early disease, but not symptoms [24]. They did point out the risk of COPD is greater in symptomatic
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persons without airflow obstruction, however there was a dissociation between structural lung damage
and symptoms. Although it is unknown what portion of subjects in our study who reported frequent
respiratory symptoms had AO by spirometry or structural changes, the presence of symptoms are
invariably important and are known to affect overall well-being and long-term outcomes [27,30–37],
and may be a better predictor of mortality than forced expiratory volume in 1 s (FEV1) [27,36,38]. In the
COPDGene study, symptomatic ever-smokers without airflow obstruction, regardless of history of
asthma, had greater activity limitation, lower pulmonary function, and more airway-wall thickening
by computed tomography than did asymptomatic ever-smokers [37].
Health impairments, respiratory symptoms, and comorbidities were common in persons at
high-risk for COPD as has been reported persons with undiagnosed COPD (31) as well as in those
with significant respiratory symptoms without airflow obstruction [37,39]. In our study, where those
at high-risk likely include undiagnosed persons, measures of physical impairment were evident by
high rates of DOE and difficulty in walking or climbing stairs. Physical impediments contribute to
deconditioning and worsened dyspnea [40], whereas mental health issues as anxiety and depression
contribute to increased respiratory symptoms [41]. Mental health effects were apparent in the high-risk
group as shown by high rates of depression and frequent mental distress, similar to that reported by
those with COPD.
The effects of gender on COPD risk were found in this study as men were more likely to be at
high-risk for COPD, and conversely women were more likely to be diagnosed with COPD. Although
women are less likely to smoke and have shorter lifetime tobacco duration than men, they are more
susceptible to the effects of tobacco [42] and use a greater portion of their lung capacity [43]. Further,
as women are more likely to report dyspnea than men [44], they may be more likely to be diagnosed
with COPD, yielding a higher disease prevalence [7] and ultimately greater associated mortality [45].
The under recognition of COPD in men represents an important health disparity warranting greater
emphasis on early diagnosis.
Consistent with our study, racial differences in COPD prevalence have previously been reported
where Caucasians have higher frequencies than Hispanics and African Americans [5,7,46]. The lower
rate of either being at high-risk for COPD or having COPD found in Hispanics and African Americans
may be related to differences in tobacco smoking, genetics, and potentially other factors, such
as healthcare access. Whereas African Americans have similar ever-smoking rates compared to
Caucasians, they have lower tobacco intensity (pack years) [47]. Compared to Caucasians, Hispanics
have lower rates of ever smoking [4]. In the current study, racial differences in COPD risk appeared to
contribute to geographic variation among states. The 2010 US census reported the Hispanic census
in the four states participating in this study as FL 26%, KY 5%, SC 5%, and TX 38% [6], consistent
with the relative prevalence of high-risk for COPD and diagnosed COPD in each state. Whereas
we found a lower prevalence of being at high-risk of COPD in African Americans than Caucasians,
one study has reported higher rates of undiagnosed COPD in African Americans, but that study was
not cross-sectional and racial differences were therefore dependent on study enrollment [48].
Tobacco smoking is the principal risk factor for COPD in the USA—we found that nearly one-half
of the study participants were ever-smokers and rates varied among states and with age. Although we
did not measure intensity, we found prolonged duration was associated with an increased likelihood
of being at high-risk for COPD as well as being diagnosed with COPD. The 25–34 years-old age group
represents an important target for smoking cessation interventions. We found COPD risk increased
significantly somewhere between 10 and 20 years of smoking, and especially ≥30 tobacco-years.
As smokers vary in their tobacco use over time, it is possible that a smoking history based on years is
more reliable than one based on years and number of packs/day or cigarettes smoked/day. In addition,
quantifying cigar and pipe smoking intensity is difficult based on pack years. Considering the long-held
use of pack years to define smoking history in the clinical setting and some of its potential inaccuracies,
reporting both pack years and tobacco-years in medical records may be a rational approach. More
research needs to be undertaken to evaluate severity of disease as well as risk of developing COPD in
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relationship to tobacco duration and intensity, and therefore the best approach to define and document
tobacco smoking use.
Limitations
Our study had several limitations including those inherent to the BRFSS, as responses were
obtained by telephone survey; therefore, we relied on self-report of medical conditions and smoking
history. COPD diagnoses were not confirmed with spirometry or review of medical records,
which could result in misclassification of respondents, however, previously, three-fourths of BRFSS
respondents with COPD reported having a diagnostic breathing test [49]. When verified by spirometry,
sensitivity has ranged from 78% to 99% for a self-report of COPD [50–52]. We did not define DOE or
SOB using standard dyspnea questions, although one could argue SOB affecting physical activities has
more value than SOB walking on an incline. Although we defined cough over the last month whereas
GOLD definition uses two-year period symptoms [14], the St George Respiratory Questionnaire uses
a one-month period to define productive cough [53]. Lastly, we did not address other non-tobacco
causes of COPD as occupation or biomass exposures, which may underestimate prevalence of being at
high-risk for COPD.
5. Conclusions
From a large recent cross-sectional respiratory symptom health survey conducted in adults in four
USA states, we provide useful insight into prevalence and burden of disease in persons at high-risk
of COPD. Whereas self-report of provider-diagnosed COPD prevalence was higher in women, men
were more likely to be characterized as high-risk for COPD. The frequencies of comorbidities and
health impairment measures were similar between COPD and high-risk for COPD groups. Among the
three respiratory symptoms measured in this study, dyspnea was the only symptom more common
in COPD than at high-risk of COPD. There was wide variation in COPD risk among the states and
among different races. Adults in the four states with COPD or at high-risk of COPD accounted for
more than three-fourths of persons in the population reporting frequent SOB. The BRFSS health survey
could be used as a tool to monitor national respiratory health in a large population and aid initiatives
to improve lung diseases by characterizing at-risk individuals and thus help support national health
strategies for COPD, such as the NHLBI National COPD Plan.
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